Pds Biotechnology Corporation · NASDAQ:PDSB
Pds Biotechnology — Investor Presentation (October 2022)
25 slides from Pds Biotechnology's investor presentation, October 2022
Slide 1: Investor Presentation
IN VESTO R P RESEN TATIO N P re c is io n D e s ig n e d Sc ie n c e Fo r Im m u n o t h e ra p y NASDAQ: PDSB | October 2022
Slide 2: Forward-Looking Statements
Fo rw a rd -Lo o k in g St a t e m e n t s Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as am
Slide 3: Company Overview
Clinical-stage Company developing targeted immunotherapies to 1 treat cancer and infectious disease Versamune® and Infectimune™ platforms leverage the body’s own 2 defense systems to induce disease-specific killer T cells and antibodies to combat cancer and infectious disease Technology developed by
Slide 4: Versamune Oncology Platform
Ve r s a m u n e ® O n c o lo g y P la t fo rm
Slide 5: Promising topline phase 2 clinical data
P r o m is in g t o p lin e P D S0 10 1 p h a s e 2 c lin ic a l d a t a Interim efficacy data from 3 oncology trials and 56 patients suggest potential long-term efficacy Versamune® Technology Platform: In-vivo tumor-specific killer (CD8+) T-cell induction HPV-positive metastatic head and neck cance
Slide 6: The PDS Biotech Differentiation
Th e P D S B io t e c h D iffe r e n t ia t io n Versamune® is designed to promote the 3 R’s T cell activation Ve rsa m u n e ® b a se d t h e ra p ie s a lso sh o w p o t e n t ia l t o 1: Generate the right type, right potency and right quantity of effective CD8+ killer T cells 12-30 % Success in
Slide 7: Versamune Platform: Designed to Recruit, Train and Arm T cells in Body
Ve r s a m u n e ® P la t fo r m D e s ig n e d t o Re c ru it , Tra in a n d Arm T c e lls in t h e B o d y References: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN respon
Slide 8: Versamune Platform Oncology Pipeline
Ve rs a m u n e ® P la t fo rm Versamune® based oncology pipeline is being developed in partnership with the leaders in immuno oncology Ca n d id a t e In d ic a t io n Co m b in a t io n PC P1 P2 P3 R P a rt n e r(s ) P D S0 10 1 (HP V16 ) Re c u rre n t /m e t a s t a t ic HP V16 -p o s it ive h e
Slide 9: PDS0101: Lead Asset
P D S0 10 1: Le a d As s e t US H P V-a s s o c ia t e d c a n c e r Designed to treat human papillomavirus in c id e n c e 2 (HPV16)-associated cancers Penile Vaginal 3% 2% $ 6 B Ma r k e t O p p o r t u n it y 1 Vulvar 9% More than 4 6 ,0 0 0 2 patients were estimated to have been diagnosed last y
Slide 10: Phase 2: PDS0101 in Combination with KEYTRUDA
P h a s e 2 : P D S0 10 1 in Co m b in a t io n w it h KEYTRUD A ® Company-sponsored trial for the potential treatment of HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002) In d ic a t io n Treatment of patients with HPV16-positive head and neck cancer whose cancer has spread o
Slide 11: Phase 2: PDS0101 + KEYTRUDA Results
P h a s e 2 : P D S0 10 1 + KEYTRUD A ® Company-sponsored trial for the potential treatment of HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002) As of last DMC meeting – to date 43 patients treated had zero grade 3 or higher treatment related adverse events N=17 Subjects w/Ima
Slide 12: Phase 2: PDS0101 + Bintrafusp alfa + M9241 (Triple Combination)
P h a s e 2 : P D S0 10 1 + B in t r a fu s p a lfa + M9 2 4 1 (Tr ip le Co m b in a t io n ) NCI-led trial for the potential treatment of HPV16-positive anal, cervical, head and neck, penile, vaginal, vulvar cancers In d ic a t io n Treatment of patients with advanced refractory HPV16-associated ca
Slide 13: Phase 2: Extended Interim Data - Efficacy and Safety
P h a s e 2 : Ex t e n d e d In t e r im D a t a – Effic a c y a n d Sa fe t y Extended interim data continue to appear to show clinical signs of efficacy, durability and safety Data updated as of October 2022 % of Patients CPI refractory alive at median 16 months 66% (19/29) % of Patients experienc
Slide 14: PDS0102: TARP Antigen
P r e -Clin ic a l O p t im iz a t io n St u d ie s 1: P D S0 10 2: TARP TARP -Sp e c ific T c e ll In d u c t io n a ft e r 2 in je c t io n s o f P D S0 10 2 An t ig e n 10 0 0 Versamune® induced CD8+ IFN -y ELISP O T St u d y killer T cells may result in the 90 0 Ra n g e o f o b s e rve d abilit
Slide 15: PDS0103: MUC1 Antigen
P D S0 10 3: MUC1 An t ig e n # o f An t ig e n -Re c o g n izin g CD8 + T Ce lls IFN-γSp o t Fo rm in g Ce lls /1X10 6 Sp le e n Ce lls Greater quantity and quality of Versamune® induced CD8+ killer T cells may result in the ability to treat breast, ovarian, lung, and colon cancers $ 10 0 B MUC1 To
Slide 16: Phase 2: PDS0101 + Chemoradiotherapy
P h a s e 2 : P D S0 10 1 + Ch e m o r a d io t h e r a p y Investigator-led trial evaluating the combination in patients with locally advanced cervical cancer (IMMUNOCERV) In d ic a t io n Treatment of patients with locally advanced cervical cancer–Stages IB3-IVA Chemoradiotherapy (CRT –Standard of
Slide 17: Phase 2: PDS0101 Monotherapy and in Combination with KEYTRUDA
P h a s e 2 : P D S0 10 1 Mo n o t h e r a p y a n d in Co m b . w it h KEYTRUD A ® Investigator-led trial evaluating potential treatments in patients with HPV-associated oropharyngeal cancer with high risk of recurrence In d ic a t io n Treatment of patients with oropharyngeal cancer prior to trans
Slide 18: Projected Milestones Through 1Q23
P ro je c t e d Mile s t o n e s Th ro u g h 1Q 20 23* 1Q 22 2Q 22 3Q 22 4 Q 22 1Q 23 2Q 23 3Q 23 P re lim in a ry d a t a fro m VERSATILE- 0 0 2 (KEYTRUD A® c o m b o ) (g o , n o g o ) Co m p le t e d e n ro llm e n t o f HP V- a s s o c ia t e d c a n c e r t ria l CP I re fra c t o ry a rm (NCI)
Slide 19: Infectimune Infectious Disease Platform
In fe c t im u n e ™ In fe c t io u s D is e a s e P la t fo rm
Slide 20: PDS Biotech's Infectimune Pipeline
P D S Bio t e c h ’s In fe c t im u n e ȃ P ip e lin e Developed in partnership with leaders in infectious disease Ca n d id a t e In d ic a t io n PC P1 P2 P3 R P a rt n e r(s ) P D S0 20 2 Un ive rs a l p re ve n t io n (in flu e n za ) o f in flu e n za P D S0 20 3 P re ve n t io n o f (SARS-Co V
Slide 21: Infectimune Pipeline Highlights: Universal Influenza Vaccines
Un iv e r s a l In flu e n z a Va c c in e s • License agreement with University of Georgia for proprietary influenza antigens In fe c t im u n e ȃ • Top-line preclinical data announced; effective P ip e lin e H ig h lig h t s delivery of flu proteins activate the critical immune signals necessary t
Slide 22: PDS0202: Universal Prevention of Influenza
P D S0 20 2: Un ive rs a l P re ve n t io n o f In flu e n za Appeared to Provide Protection in Preclinical Study in Keeping Animals Alive and Healthy Against Challenge with Flu Virus % o f P ro t e c t io n o f Su b je c t s Ch a lle n g e d w it h t h e Flu Viru s 10 0 % 10 0 % 10 0 % 10 0 % % of
Slide 23: PDS Biotech Management
P D S B io t e c h Ma n a g e m e n t H is t o r ic a l s u c c e s s in t h e d e v e lo p m e n t a n d c o m m e r c ia liz a t io n o f le a d in g p h a r m a c e u t ic a l p r o d u c t s • Senior executive experience with management of strategy and execution at both large pharma and biotechs
Slide 24: Company Overview
Clinical-stage Company developing targeted immunotherapies to 1 treat cancer and infectious disease Versamune® and Infectimune™ platforms leverage the body’s own 2 defense systems to induce disease-specific killer T cells and antibodies to combat cancer and infectious disease Technology developed by
Slide 25: Investor Presentation
IN VESTO R P RESEN TATIO N P re c is io n D e s ig n e d Sc ie n c e Fo r Im m u n o t h e ra p y NASDAQ: PDSB | October 2022
PDS Biotechnology — Investor Presentation (October 2022) on 6ix